RIVERMARK MEDICAL ANNOUNCES COMPLETION OF EXPANDED INDICATION STUDY FOR THE FLOSTENT™ SYSTEM
MILWAUKEE, Jan. 8, 2024 /PRNewswire/ -- Rivermark Medical, a company dedicated to developing a novel therapeutic device for benign prostatic hyperplasia (BPH), announced today the successful completion of its RAPID-UR study, an extended indication study that evaluated the use of the Company's FloStent System in patients suffering urinary retention due to BPH. The pilot study included 11 patients, and procedures were performed by Drs. Ingrid Perscky and Ruben Urena at the Pacifica Salud Costa del Este Hospital in Panama City, Panama.
- Ingrid Perscky and Ruben Urena at the Pacifica Salud Costa del Este Hospital in Panama City, Panama.
- Urinary retention (UR) refers to a patient's inability to pass urine, often requiring placement of a temporary indwelling catheter for relief.
- We are confident this expanded application of the FloStent System will address this critical unmet need."
- Clinical data from the RAPID-I FIH study, along with results from the expanded indication study, RAPID-UR, will be presented at upcoming Urology congresses.